# Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

> **NCT01308294** · PHASE1,PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 16 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** 2 vaccine injections in 1 limb
- **BIOLOGICAL:** 2 vaccine injections in distinct limbs
- **BIOLOGICAL:** 2 "vaccine injections" in distinct limbs

## Key facts

- **NCT ID:** NCT01308294
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Low enrollment rate
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308294, "Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01308294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*